PRMT5, protein arginine methyltransferase 5, 10419

N. diseases: 131; N. variants: 0
Disease: Childhood Glioblastoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.080 Biomarker disease BEFREE Suppression of PRMT5 occurs in methylthioadenosine phosphorylase (MTAP)-deficient glioblastoma cells and attenuates the expression of RNF168, leading to destabilization of H2AX by E3 ubiquitin ligase SMURF2. 31533041 2019
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.080 Biomarker disease BEFREE The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma. 31473880 2019
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.080 Biomarker disease BEFREE Here we show that Myc/PRMT5 protein complex includes PRMT1, in both HEK293T and glioblastoma stem cells (GSCs). 31685892 2019
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.080 Biomarker disease BEFREE Protein arginine methyltransferase 5 (PRMT5) is an epigenetics related enzyme that has been validated as an important therapeutic target for glioblastoma and mantel cell lymphoma. 30172110 2018
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.080 AlteredExpression disease BEFREE PRMT5 is ubiquitously expressed in most tissues and its expression has been shown to be elevated in several cancers including breast cancer, gastric cancer, glioblastoma, and lymphoma. 30034588 2018
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.080 Biomarker disease BEFREE PRMT5 as a druggable target for glioblastoma therapy. 29106602 2018
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.080 Biomarker disease BEFREE Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells. 26563484 2015
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.080 Biomarker disease BEFREE Together, our findings defined PRMT5 as a candidate prognostic factor and therapeutic target in glioblastoma, offering a preclinical justification for targeting PRMT5-driven oncogenic pathways in this deadly disease. 24453002 2014